Table 3.
Chimerism Analyses After-HSCT and HSV-Tk DLI
| UPN | Day +25 | Day +100 | Day +200 | 1 year | 2 years | CD4+cells, >2 years | CD8+cells, >2 years | Last follow-up |
|---|---|---|---|---|---|---|---|---|
| 914 | 99% | 82% | 54% | 72% | 100% | ND | ND | 100% |
| 919 | 86% | 87% | 94% | 87% | 96% | 100% | 78% | 97% |
| 1021 | 100% | 96% | 97% | 95% | 96% | 68% | 33% | Relapse/100% |
| 1040 | 100% | 100% | 100% | 100% | 58% | 100% | 100% | Relapse |
| 1048 | 87% | 71% | 67% | 66% | 78% | 77% | 54% | 92% |
| 1108 | 100% | 81% | 85% | 85% | 93% | 96% | 81% | 98% |
| 1159 | 100% | 95% | 99% | 99% | 99% | ND | ND | 99% |
| 1190 | 100% | 93% | 96% | 94% | 96% | 93% | 95% | 95% |
| 1208 | 94% | 100% | 100% | 100% | 64% | NA | NA | Relapse |
Peripheral blood of all patients was screened routinely for donor chimerism by PCR. Here the percent (%) donor chimerism in peripheral blood mononuclear cells (PBMCs) is shown for days +25, +100, and +20; 1 and 2 years post-HSCT; and at follow-up (most recent visit, up to 7 years post-DLI). Subgroup chimerism analyses (CD4+ and CD8+ cells, >2 years) were performed in all patients with mixed chimerism 2 years post-HSCT.
DLI, donor lymphocyte infusion; HSCT, hematopoietic stem cell transplantation; HSV-Tk, herpes simplex virus thymidine kinase; NA, not applicable; UPN, unique patient number. ND, not detectable.